Baquinor/Baquinor Forte Pregnancy

Rating: 1 - 2 review(s)
Was this medicine useful for you?

Pregnancy of Baquinor/Baquinor Forte in details

infoPregnancy is always a special situation where every action or side effect of the drug varies when compared to a situation of a non-pregnant patient. It is not only because the pregnant woman's metabolism differs due to the hormonal and other changes happened to her, but also because every medicine or its metabolite passes to the baby and shows its action there. The only thing is, be cautious, attentive and well supervised when you take any single drug in pregnancy. The interactions can vary in pregnancy, and the dosage may differ as well. Strict supervision of the Physician is mandatory.

Contraindicated in pregnancy (safety and efficacy in women during pregnancy has not been established); Baquinor/Baquinor Forte crosses the placenta, excreted in breast milk.

In experimental studies found that it causes arthropathy. In experiments on rats and mice treated with Baquinor/Baquinor Forte in doses exceeding the usual daily dose for a person 6 times, adverse effects on the fetus is not revealed. In experiments on rabbits treated with oral dose of Baquinor/Baquinor Forte 30 and 100 mg / kg, it is shown that the drug causes disruption of the gastrointestinal tract, leading to loss of body weight in females and increase the number of miscarriages but teratogenicity not found. When IV introduction to the doses of 20 mg / kg Baquinor/Baquinor Forte did not exert toxic effects on the mother and embryo, showed no teratogenicity. The use of local forms of Baquinor/Baquinor Forte in pregnancy is possible if the anticipated benefits exceed the potential risk to the fetus.

Category of the fetus by FDA - C.

Baquinor/Baquinor Forte is excreted in breast milk, so the period of lactation should decide, stop taking Baquinor/Baquinor Forte or breastfeeding based on the degree of importance of the use of drugs for the mother.

With careful use of local forms of Baquinor/Baquinor Forte in breast-feeding (not known whether Baquinor/Baquinor Forte is excreted in breast milk when applied topically).

Baquinor/Baquinor Forte breastfeeding

infoWhen a drug is taken when the patient is breast feeding, a part of the drug is secreted in her breast milk and is passed to the baby. The dosage of the medicine to mother and baby are different, and many drugs actions are side effects when you take them without a disease, and what if you the baby takes them without a disease? What if the drug is contraindicated in newborns, infants or children? So, breastfeeding is a very alarming situation when the mother is on medications. Ask your Physician or Pediatrician about the effect of the drug on the baby and how much is excreted in breast milk and if it harms the baby!

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Yes Comments: -The effects in the nursing infant are unknown; potential risk of serious side effects (including articular damage) in the nursing infant. -This drug is considered compatible with breastfeeding by the American Academy of Pediatrics.

Cartilage erosion and arthropathy have been reported in immature animals giving rise to concern over toxic effects in the developing joints of nursing infants; however, some studies suggest risk is low. Absorption of the small amounts of fluoroquinolones in milk may be blocked by the calcium in milk; data insufficient to prove or disprove. Levels found in breast milk have ranged from 85% (at 24 hours postdose) to 214% (at 4 hours postdose) of maternal serum level. Postpartum (time not specified), 10 lactating women received 750 mg orally every 12 hours for 3 doses. At 2 hours after the third dose, milk drug levels were highest and averaged 3.79 mg/L. Milk levels then declined and averaged 2.26 mg/L at 4 hours, 0.86 mg/L at 6 hours, 0.51 mg/L at 9 hours, 0.2 mg/L at 12 hours, and 0.02 mg/L at 24 hours after the dose. Based on peak milk levels in this study, an exclusively breastfed infant would receive up to 0.57 mg/kg daily (estimated) with this maternal dose regimen, which is much lower than the dose used to treat neonates. A single 500 mg oral dose was given to a mother recovering from acute renal failure; this dose was administered with a prenatal vitamin and ferrous sulfate, which would be expected to decrease Baquinor/Baquinor Forte bioavailability. Milk levels were 3.5 mg/L at 4, 8, and 12 hours after the dose and 2.3 mg/L at 16 hours after the dose. Levels were probably elevated and elimination prolonged due to the renal dysfunction. A woman took 500 mg orally daily for 10 days. Drug level in breast milk was 0.98 mg/L at 10 hours and 40 minutes after the last dose. After breastfeeding once (8 hours after the dose), this drug was not detectable (less than 30 mcg/L) in the infant's serum 2.7 hours after nursing. In 1 case report, a 2-month-old girl with history of necrotizing enterocolitis developed perforated pseudomembranous colitis, most likely due to ingestion of this drug via her mother's milk, and subsequently required a bowel resection. The mother admitted self-treatment while breastfeeding her infant. This drug was used as part of multi-drug regimens to treat 3 pregnant women with multidrug-resistant tuberculosis throughout pregnancy and postpartum. Their 3 infants were breastfed (extent and duration not specified). At age 1.25, 1.8, and 3.9 years, 2 of the children were developing normally while the other child had failure to thrive, possibly due to contracting tuberculosis after birth. This drug is recommended by the US CDC as a preferred agent for postexposure prophylaxis and treatment of anthrax in lactating women. The Working Group on Civilian Biodefense has recommended this drug as an alternative for plague.

See references

References for pregnancy information

  1. Dennis DT, Inglesby TV, Henderson DA, et al "Tularemia as a biological weapon: medical and public health management." JAMA 285 (2001): 2763-73
  2. "Product Information. Cipro XR (Baquinor/Baquinor Forte)." Bayer Pharmaceutical Inc, West Haven, CT.
  3. Inglesby TV, Dennis DT, Henderson DA, et al "Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense." JAMA 283 (2000): 2281-90
  4. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  5. Ramakrishnan K, Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42
  6. "Product Information. Cipro (Baquinor/Baquinor Forte)." Bayer, West Haven, CT.
  7. Inglesby TV, O'Toole T, Henderson DA, et al. "Anthrax as a biological weapon, 2002: updated recommendations for management." JAMA 287 (2002): 2236-52
  8. Schaefer C, Amouraelefant E, Vial T, Ornoy A, Garbis H, Robert E, Rodriguezpinilla E, Pexieder T, Prapas N, Merlob P "Pregnancy outcome after prenatal quinolone exposure: evaluation of a case registry of the european network of teratology information services (ENTIS)." Eur J Obstet Gynecol Reprod Biol 69 (1996): 83-9
  9. Cerner Multum, Inc. "Australian Product Information." O 0
  10. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Giamarellou H, Kolokythas E, Petrikkos G, Gazis J, Aravantinos D, Sfikakis P "Pharmacokinetics of three newer quinolones in pregnant and lactating women." Am J Med 87 (1989): s49-51
  2. Gardner DK, Gabbe SG, Harter C "Simultaneous concentrations of Baquinor/Baquinor Forte in breast milk and in serum in mother and breast-fed infant." Clin Pharm 11 (1992): 352-4
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Cover DL, Mueller BA "Baquinor/Baquinor Forte penetration into human breast milk: a case report." Ann Pharmacother 24 (1990): 703-4
  5. Cerner Multum, Inc. "Australian Product Information." O 0
  6. Sachs HC; Committee on Drugs "The transfer of drugs and therapeutics into human breast milk: an update on selected topics. " Pediatrics 132 (2013): e796-809
  7. "Product Information. Cipro XR (Baquinor/Baquinor Forte)." Bayer Pharmaceutical Inc, West Haven, CT.
  8. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  9. "Product Information. Cipro (Baquinor/Baquinor Forte)." Bayer, West Haven, CT.
  10. Meaney-Delman D, Zotti ME, Greanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women "Special considerations for treatment of anthrax in pregnant and postpartum women. Available from: URL:" ([2014 Feb]):
  11. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  12. Antibiotic Expert Group. "Therapeutic Guidelines: Antibiotic. 14th ed." Melbourne, Australia, AK: Therapeutic Guidelines Ltd. (2010):
  13. "American Academy of Pediatrics. Committee on Drugs. The transfer of drugs and other chemicals into human milk." Pediatrics 108 (2001): 776-89



  1. DailyMed. "CIPROFLOXACIN; DEXAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". (accessed September 17, 2018).
  2. PubMed Health. "Ciprofloxacin (Into the eye) (Ciloxan): This section provide the link out information of drugs collectetd in PubMed Health. ". (accessed September 17, 2018).
  3. Human Metabolome Database (HMDB). "Ciprofloxacin: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". (accessed September 17, 2018).


Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 14 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2020 All Rights Reserved